Author (Corporate) | European Medicines Agency |
---|---|
Series Title | Press Release |
Series Details | EMA/263105/2012 (20.4.12) |
Publication Date | 20/04/2012 |
Content Type | News |
The European Medicines Agency (EMA), on 20 April 2012, gave new advice to healthcare professionals to reduce the risk of adverse effects on the heart associated with the use of the multiple sclerosis (MS) treatment Gilenya (fingolimod). |
|
Source Link | Link to Main Source http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2012/04/news_detail_001498.jsp&mid=WC0b01ac058004d5c1&murl=menus/news_and_events/news_and_events.jsp |
Related Links |
|
Subject Categories | Health |
Countries / Regions | Europe |